期刊文献+

雷替曲塞联合奥沙利铂及局部放疗对晚期直肠癌的疗效及不良反应观察

Observation of the Efficacy and Side Effects of Retrexed Combined with Oxaliplatin and Local Radiotherapy on Advanced Rectal Cancer
下载PDF
导出
摘要 目的探讨晚期直肠癌采用雷替曲塞与奥沙利铂及局部放疗联合治疗的临床效果及不良反应。方法选取2015年6月~2017年6月我院收治的50例晚期直肠癌患者。根据治疗方案不同分为观察组和对照组各25例。观察组采用雷替曲塞联合奥沙利铂化疗,对照组采用氟尿嘧啶联合奥沙利铂化疗,两组均联合直肠病灶放疗,比较两组临床疗效及不良反应情况。结果观察组患者临床治疗有效率为88.0%,明显高于对照组的60.0%,疾病控制率为96.0%,显著高于对照组的72.0%,差异有统计学意义(P<0.05);观察组呕吐发生率为32.0%、腹泻发生率为20.0%,对照组为64.0%和60.0%,观察组中性粒细胞减少发生率60.0%、转氨酶升高48.0%,对照组为28.0%和20.0%,差异显著性(P<0.05)。结论雷替曲塞联合奥沙利铂及局部放疗方案治疗晚期直肠癌,其有效率显著,安全性较高,值得临床推广。
出处 《现代诊断与治疗》 CAS 2017年第23期4334-4335,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献9

二级参考文献86

  • 1Andre T, Louvet C, Maindrault-Coebel F,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFI- RI) for pretreated metastatic colorectal cancer [ J ]. Eur J Cancer, 1999,35 (9) : 1343 - 7.
  • 2Maindrauh-Goebel F, de Gramont A,Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer[ J ].Ann Onco1,2000,11 ( 11 ) : 1477 - 1483.
  • 3Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic eoloreetal cancer: the NO16966 trial [ J]. Clin Coloreetal Cancer,2006,6(4) :261 - 264.
  • 4Jackman AL, Farrugia DC, Gibsonw, et al. ZD1694 (tomudex) : a new thymidylate synthase inhibitor with activity in colorectal cancer [ J]. Eur J Cancer, 1995,31A ( 7/8 ) : 1277 - 1282.
  • 5Aschele C, Baldo C, Sobrero AF, et al. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells [ J ]. Clin Cancer Res, 1998,4 ( 5 ) :1323 - 1330.
  • 6Laudani A, Gebbia V, Leonardi V, et al. Activity and toxicity of oxaliplatin plus raltit rexed in 5-fluorouracil ref ractory meta-static colorectal adeno2carcinoma [ J ]. Anticancer Res,2004,24(2) :1139 - 1142.
  • 7Cortinovis D, Bajetta E, Di Bartolomeo M, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer [ J ]. Tumori ,2004,90 ( 2 ) : 186 - 191.
  • 8Martoni A, Mini E, Pinto C, et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study [ J]. Anticancer Res,2003,23 (1B): 687 -691.
  • 9Popov I, Garrato A, Sobrero A, et al. Raltitrexed (tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 ( PETACC-1 ) [ J ]. European Journal of Cancer,2008,44( 15 ) :2204 - 2211.
  • 10van CUTSEM E, OLIVEIRA J. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2009, 20 Suppl 4: 61-63.

共引文献193

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部